[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.48.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 704
Citations 0
Viewpoint
ONLINE FIRST
November 28, 2012

Sherley v Sebelius and the Future of Stem Cell Research

Author Affiliations

Author Affiliations: Harvard Law School, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Cambridge, Massachusetts (Mr Cohen); Harvard Law School, Cambridge, Massachusetts (Mr Feigenbaum); and The Warren Alpert Medical School, Brown University, Providence, Rhode Island (Dr Adashi). Mr Cohen is currently a fellow at the Radcliffe Institute for Advanced Studies at Harvard University, Cambridge, Massachusetts.

JAMA. 2012;308(20):2087-2088. doi:10.1001/jama.2012.36633

It has now been close to 15 years since the derivation of the first human embryonic stem cell (hESC) line.1 However, the legal, legislative, and political strife over the federal funding of hESC research continues unabated. The stakes are considerable because early translational efforts have entered the clinical trial arena.2 In this Viewpoint we trace the resolution of the latest legal challenge to the federal funding of hESC research and reflect on the future course of this important debate.

First Page Preview View Large
First page PDF preview
First page PDF preview
×